EP2909172A1 - Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp - Google Patents

Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp

Info

Publication number
EP2909172A1
EP2909172A1 EP13779184.4A EP13779184A EP2909172A1 EP 2909172 A1 EP2909172 A1 EP 2909172A1 EP 13779184 A EP13779184 A EP 13779184A EP 2909172 A1 EP2909172 A1 EP 2909172A1
Authority
EP
European Patent Office
Prior art keywords
methoxy
indol
pyridin
iodo
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13779184.4A
Other languages
German (de)
English (en)
Inventor
Zhi Chen
Shawn David Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP2909172A1 publication Critical patent/EP2909172A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal of an inflammatory disease or disorder, and in particular to substituted indole compounds, their manufacture, pharmaceutical compositions containing them and their use as Transient Receptor Potential (TRP) channel antagonists.
  • TRP Transient Receptor Potential
  • the invention relates in particular to a compound of formula (I)
  • X is -CH- or nitrogen
  • Rl is lower alkoxy
  • R2 is halogen
  • R3 is hydrogen or lower alkoxy; one of R4 and R4' is hydrogen or lower alkyl and the other is hydrogen or -C(0)-R5; and
  • TRP channels are a class of ion channels found on the plasma membrane of a variety of human (and other animal) cell types. There are at least 28 known human TRP channels which are broken into a number of families or groups based upon sequence homology and function.
  • TRPAl is a non-selective cation conducting channel that modulates membrane potential via flux of sodium, potassium and calcium. TRPAl has been shown to be highly expressed in the human dorsal root ganglion neurons and peripheral sensory nerves. In humans, TRPAl is activated by a number of reactive compounds such as acrolein, allylisothiocyanate, ozone as well as unreactive
  • TRPAl agonists are irritants that cause pain, irritation and neurogenic inflammation in humans and other animals. Therefore, it would be expected that TRPAl antagonists or agents that block the biological effect of TRPAl channel activators would be useful in the treatment of diseases such as asthma and its exacerbations, chronic cough and related maladies as well as being useful for the treatment of acute and chronic pain. Recently, it has also been shown that products of tissue damage and oxidative stress, e.g. 4-hydroxynonenal and related compounds, activate the TRPAl channel.
  • the invention also provides for pharmaceutical compositions comprising the compounds, methods of using the compounds and methods of preparing the compounds.
  • moiety refers to an atom or group of chemically bonded atoms that is attached to another atom or molecule by one or more chemical bonds thereby forming part of a molecule.
  • variables Rl to R6 of formula I refer to moieties that are attached to the core structure of formula I by a covalent bond.
  • substituted refers to the fact that at least one of the hydrogen atoms of that moiety is replaced by another substituent or moiety.
  • lower alkyl substituted by halogen refers to the fact that one or more hydrogen atoms of a lower alkyl (as defined below) is replaced by one or more halogen atoms (e.g. trifluoromethyl, difluoromethyl, fluoromethyl, chloromethyl, etc.)
  • alkyl refers to an aliphatic straight-chain or branched-chain saturated hydrocarbon moiety having 1 to 20 carbon atoms. In particular embodiments the alkyl has 1 to 10 carbon atoms.
  • lower alkyl refers to an alkyl moiety having 1 to 7 carbon atoms. In particular embodiments the lower alkyl has 1 to 4 carbon atoms and in other particular embodiments the lower alkyl has 1 to 3 carbon atoms. Examples of lower alkyls include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, in particular methyl.
  • alkoxy denotes a group of the formula -O-R', wherein R' is an alkyl group.
  • R' is an alkyl group.
  • lower alkoxy refers to an alkoxy moiety where the alkyl group R' has 1 to 7 carbon atoms.
  • alkoxy moieties include methoxy, ethoxy, isopropoxy, and tert-butoxy, in particular methoxy and tert-butoxy.
  • halo refers to a substituent fluoro, chloro, bromo or iodo, in particular chloro or iodo.
  • hydrogen refers to the moiety of a hydrogen atom (-H) and not H 2 .
  • benzene alone or in combination with other groups, means the phenyl moiety.
  • a compound of the formula or “a compound of formula” or “compounds of the formula” or “compounds of formula” refers to any compound selected from the genus of compounds as defined by the formula (including any pharmaceutically acceptable salt or ester of any such compound if not otherwise noted).
  • salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. Salts may be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, salicylic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, N- acetylcystein and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid
  • salts may be prepared by the addition of an inorganic base or an organic base to the free acid.
  • Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts and the like.
  • Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins and the like.
  • the compounds of the present invention can be present in the form of
  • the compounds of the present invention can also be present in the form of pharmaceutically acceptable esters (i.e., the methyl and ethyl esters of the acids of formula I to be used as prodrugs).
  • the compounds of the present invention can also be solvated, i.e. hydrated. The solvation can be effected in the course of the manufacturing process or can take place i.e. as a consequence of hygroscopic properties of an initially anhydrous compound of formula (I) (hydration).
  • isomers Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers” and fall within the scope of the invention. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Diastereomers are stereoisomers with opposite configuration at one or more chiral centers which are not enantiomers. Stereoisomers bearing one or more asymmetric centers that are non- superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center or centers and is described by the R- and S-sequencing rules of Cahn, Ingold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
  • a therapeutically effective amount of a compound means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the skill in the art.
  • the therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage will be adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated.
  • a daily dosage of about 0.1 mg to about 5,000 mg, 1 mg to about 1,000 mg, or 1 mg to 100 mg may be appropriate, although the lower and upper limits may be exceeded when indicated.
  • the daily dosage can be administered as a single dose or in divided doses or, for parenteral administration, it may be given as continuous infusion.
  • pharmaceutically acceptable carrier is intended to include any and all material compatible with pharmaceutical administration including solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and other materials and compounds compatible with pharmaceutical
  • compositions of the invention are incompatible with the active compound, use thereof in the compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • Useful pharmaceutical carriers for the preparation of the compositions hereof can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders, enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid-protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like.
  • the carrier can be selected from the various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • formulations for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile.
  • Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • compositions may be subjected to conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers and the like.
  • suitable pharmaceutical carriers and their formulation are described in Remington's Pharmaceutical Sciences by E. W. Martin.
  • Such compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
  • an effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt or ester thereof is administered via any of the usual and acceptable methods known in the art, either singly or in
  • the compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form of solid, liquid or gaseous dosages, including tablets and suspensions.
  • the administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum.
  • the therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
  • a lipophilic salt such as pamoic acid
  • the invention relates in particular to:
  • a compound of formula (I) wherein R2 is iodine or chlorine;
  • a compound of formula (I) wherein R3 is hydrogen or methoxy;
  • lower alkyl is advantageously methyl.
  • alkoxy is advantageously tert.-butoxy.
  • the invention provides for a pharmaceutical composition, comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier.
  • the invention provides for a compound according to formula (I) for use as a therapeutically active substance.
  • the invention provides for the use of a compound according to formula (I) for the treatment or prophylaxis of a respiratory disorder.
  • respiratory disorders are chronic obstructive pulmonary disorder
  • the invention provides for the use of a compound according to formula (I) for the preparation of a medicament for the treatment or prophylaxis of a respiratory disorder.
  • the invention provides for a compound according to formula (I) for use in the treatment or prophylaxis of a respiratory disorder.
  • the invention provides for a method for treating a respiratory disorder selected from chronic obstructive pulmonary disorder (COPD), asthma, allergic rhinitis and bronchospasm, comprising the step of administering a therapeutically effective amount of a compound according to formula (I) to a subject in need thereof.
  • COPD chronic obstructive pulmonary disorder
  • asthma asthma
  • allergic rhinitis allergic rhinitis
  • bronchospasm comprising the step of administering a therapeutically effective amount of a compound according to formula (I) to a subject in need thereof.
  • the starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser 's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplemental; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40.
  • the starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
  • the reactions described herein preferably are conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, more preferably from about 0 °C to about 125 °C, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 20 °C.
  • R3 hvdroaen or lower alkoxv
  • R1 lower alkoxy
  • R2 halogen
  • compound 2 can be made by reacting 3-nitroanaline and di- tert-dicarbonate in the presence of a catalyst, such as pyridine-4-ylamine, and a solvent, such as THF.
  • a catalyst such as pyridine-4-ylamine
  • a solvent such as THF
  • the resultant (3-nitro-phenyl)-carbamic acid tert-butyl ester 2 can then be placed into solution with THF and reacted with ((trimethylsilyl)methyl)magnesiumchloride.
  • a solution of 2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone in THF can then be added and allowed to react under conditions known to a skilled artisan to afford (3-nitro-4- trimethylsilanylmethyl-phenyl)-carbamic acid tert-butyl ester 3.
  • Tetra-butylammonium fluoride can then be added to a solution of ester 3 and 4-iodo-2-methoxynicotinaldehyde in THF to afford ⁇ 4-[2-hydroxy-2-(4-iodo-2-methoxy-pyridin-3-yl)-ethyl]-3-nitro- phenylj-carbamic acid tert-butyl ester 4.
  • a solution of compound 4 in turn, can be added to 2,2,2-trifluoroacetic anhydride and allowed to react to afford trifluoro-acetic acid 2-(4-tert-butoxycarbonyl-amino-2-nitro-phenyl)- 1 -(4-iodo-2-methoxy-pyridin-3- yl)-ethyl ester 5.
  • a solution of crude trifluoro-acetic acid 2-(4-tert-butoxycarbonyl-amino-2-nitro- phenyl)-l-(4-iodo-2-methoxy-pyridin-3-yl)-ethyl ester 5 in THF can then be added to 8- diazabicyclo[5.4.0]undec-7-ene.
  • a solution of [2-(4-iodo-2-methoxy-pyridin-3-yl)-lH-indol-6-yl]-carbamic acid tert-butyl ester 7 can be added to an acid such as 2,2,2-trifluoroacetic acid to afford compound 8.
  • an anhydride such as 2,2,2-trifluoroacetic anhydride
  • compound 8 followed with extraction, filtration and separation steps known in the art can afford compound 1, wherein the R groups and X can be those as described, for example, in the Examples and claims below.
  • the compounds of the present invention can be prepared using appropriate starting materials according to the methods described generally herein and/or by methods available to one of ordinary skill in the art.
  • Analogix ® IntelliFlash280TM chromatography instrument from Analogix Inc., a subsidiary of Varian Inc.
  • silica gel brand and pore size utilized were: (1) KP-SILTM 60 A, particle size: 40-60 micron (from Biotage AB); (2) Silica Gel CAS registry No: 63231-67-4, particle size: 47-60 micron; or (3) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore size: 200-300 mesh or 300-400 mesh.
  • Reverse-phase preparative HPLC was performed using a Waters ® Delta- PrepTM 3000 HPLC system from Waters Corporation using one or more of the following columns: a Varian Pursuit ® C-18 column (10 ⁇ , 20 x 150 mm) from Varian, Inc., an XbridgeTM Prep C 18 column (5 ⁇ , OBDTM 20 x 100 mm) from Waters Corporation, or a
  • Mass spectrometry (MS) or high resolution mass spectrometry (HRMS) was performed using a Waters ® ZQTM 4000 (from Waters Corporation), a Waters ® Quattro microTM API (from Waters Corporation), a Micromass ® Platform II (from Micromass, a division of Waters Corporation), a Bruker ® Apex ® II FTICR with a 4.7 Tesla magnet (from Bruker Corporation), a Waters ® Alliance ® 2795-ZQTM2000 (from Waters
  • Mass spectra data generally only indicates the parent ions unless otherwise stated. MS or HRMS data is provided for a particular intermediate or compound where indicated.
  • Nuclear magnetic resonance spectroscopy was performed using a Varian ® Mercury300 NMR spectrometer (for the 1H NMR spectra acquired at 300 MHz) and a Varian ® Inova400 NMR spectrometer (for the 1H NMR spectra acquired at 400 MHz) both from Varian Inc. NMR data is provided for a particular intermediate or compound where indicated. All reactions involving air-sensitive reagents were performed under an inert atmosphere. Reagents were used as received from commercial suppliers unless otherwise noted.
  • Penicillin-Spreptomycin solution (100X) GIBCO #15140-122)
  • tetracycline was added to blasticidin/zeocin-free media at a final concentration of lug/ml. Experiments were run at 24 h post induction.
  • Cal-3 NW Calcium dye was prepared by dissolving the contents of one vial with 500 ml Hank's Balanced Salt Solution containing 20mM HEPES.
  • Adjustments of volumes and concentrations were made at time of titration to reflect desired final assay concentrations. Compounds were tested at either 20 ⁇ three folds dilution 11 steps out or 30 ⁇ two folds dilution 11 steps out. 3 ⁇ 1 of diluted compound were transferred into Weidmann 384-well plate in duplicates side-by- side.
  • Compound plates were resuspended with lOOul of HBSS/20mM HEPES/0.005% BSA buffer (Compound Buffer): column 1A-H: buffer/DMSO (bk) column 2A-H: AP-18( control antagonist for CHOK1 TRPA1 cells) column 1I-P: ATP (control for CHOK1 teton cells) column 2 I-P: 2APB (control antagonist for CHOK1/TRPM8 cells).
  • both the cell and compound plates were brought to the FLIPR and 20ul of the diluted compounds/antagonist/bk were transferred to the cell plates by the FLIPR. Plates were then incubated for 30' at room temperature. After 30' incubation, plates were returned to the FLIPR and 20ul of 4.5X Cinnamaldehyde was added to the cell plates.
  • fluorescence readings were taken simultaneously from all 384 wells of the cell plate every 1.5 seconds. Five readings were taken to establish a stable baseline, then 20ul of sample was rapidly (30ul/sec) and simultaneously added to each well of the cell plate.
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate then mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • the components are sieved and mixed and filled into capsules of
  • Injection solutions can have the following composition:
  • the active ingredient is dissolved in a mixture of Polyethylene glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by addition of acetic acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) ainsi que leurs sels pharmaceutiquement acceptables. De plus, la présente invention concerne des procédés de fabrication et d'utilisation des composés de formule (I), ainsi que des compositions pharmaceutiques contenant ces composés. Les composés de formule (I) peuvent être utilisés en tant que médicaments.
EP13779184.4A 2012-10-17 2013-10-14 Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp Withdrawn EP2909172A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714957P 2012-10-17 2012-10-17
PCT/EP2013/071377 WO2014060328A1 (fr) 2012-10-17 2013-10-14 Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp

Publications (1)

Publication Number Publication Date
EP2909172A1 true EP2909172A1 (fr) 2015-08-26

Family

ID=49385243

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13779184.4A Withdrawn EP2909172A1 (fr) 2012-10-17 2013-10-14 Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp

Country Status (11)

Country Link
US (1) US9388166B2 (fr)
EP (1) EP2909172A1 (fr)
JP (1) JP2015534957A (fr)
KR (1) KR20150070290A (fr)
CN (1) CN104755461A (fr)
BR (1) BR112015008564A2 (fr)
CA (1) CA2888369A1 (fr)
HK (1) HK1207379A1 (fr)
MX (1) MX2015004500A (fr)
RU (1) RU2015115677A (fr)
WO (1) WO2014060328A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170298081A1 (en) * 2014-08-08 2017-10-19 Kasuma Partners Inc. Condensed heterocyclic compound
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TW201835070A (zh) * 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091407A1 (fr) * 2010-01-25 2011-07-28 Glaxosmithkline Llp Antagonistes de trpv4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
PL1986633T3 (pl) * 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
EP2170396B1 (fr) * 2007-08-03 2016-12-21 Summit Corporation Plc Combinaisons de médicaments pour le traitement de la dystrophie musculaire de duchenne
CN102427729B (zh) * 2009-03-27 2014-09-03 默沙东公司 丙型肝炎病毒复制的抑制剂
MX2012003539A (es) * 2009-09-24 2012-04-30 Hoffmann La Roche Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
EP2606031B1 (fr) * 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Inhibiteurs de l'autotaxine et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091407A1 (fr) * 2010-01-25 2011-07-28 Glaxosmithkline Llp Antagonistes de trpv4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014060328A1 *

Also Published As

Publication number Publication date
JP2015534957A (ja) 2015-12-07
CN104755461A (zh) 2015-07-01
MX2015004500A (es) 2015-07-06
HK1207379A1 (en) 2016-01-29
US9388166B2 (en) 2016-07-12
US20150218133A1 (en) 2015-08-06
RU2015115677A (ru) 2016-12-10
KR20150070290A (ko) 2015-06-24
CA2888369A1 (fr) 2014-04-24
BR112015008564A2 (pt) 2017-07-04
WO2014060328A1 (fr) 2014-04-24

Similar Documents

Publication Publication Date Title
AU2013365742B2 (en) Autotaxin inhibitors
CA3035999C (fr) Derives heterocycliques de benzene fusionne et composition pharmaceutique renfermant lesdits derives
US9388166B2 (en) 6-aminoindole derivatives as TRP channel antagonists
JP2010526866A (ja) 神経変性疾患の治療のためのアリールアミドピリミドン誘導体
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
KR20080089413A (ko) 카나비노이드 ｃｂ1 수용체 조절자로서의4,5-디하이드로-(1ｈ)-피라졸 유도체
US20100197668A1 (en) 1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-a][1,4]-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
KR20220035950A (ko) 염증성 기도 질환 또는 섬유성 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 n-메틸, n-(6-(메톡시)피리다진-3-일) 아민 유도체
TWI770841B (zh) 作為組蛋白脫乙醯基酶６抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物
AU2011336217B2 (en) KAT II inhibitors
US6395905B1 (en) Tetrahydroindazole derivatives as ligands for GABA-A α 5 receptors
US9359337B2 (en) Acetamide derivatives
US9394304B2 (en) Imidazopyridine derivatives
JP3786983B2 (ja) ピロリジノン誘導体
WO2018211323A1 (fr) Composés hétérocycliques pour traiter une maladie
JP5536771B2 (ja) セロトニン作動性活性を有する化合物、その製造方法およびそれを含む医薬組成物
CN115677703A (zh) 吡啶酮类化合物及其用途
WO2010092286A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
KR20050023401A (ko) 무스카린 수용체 길항제로서 사용가능한 3,6-이치환된아자비시클로 [3.1.0]헥산 유도체
JPWO2006115134A1 (ja) 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160502

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160913